Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

The European Medicines Agency Validates and Accepts Cell Therapeutics’ Marketing Authorization Application for Pixuvri™

November 17, 2010 By Bio-Medicine.Org

SEATTLE, Nov. 18, 2010 /PRNewswire/ — Cell Therapeutics, Inc.
(“CTI”) (Nasdaq and MTA: CTIC) announced today that CTI’s Marketing
Authorization Application (“MAA”) seeking approval for
Pixuvri™ (pixantrone dimaleate) for the treatment of adult
patients with multiply relapsed or refractory aggressive
non-Hodgkin’s lymphoma (“NHL”) was validated and accepted for
review by the European Medicines Agency (“EMA”). Validation
indicates that the application is complete and that the EMA’s
review process has begun.

“We look forward to working with our rapporteurs and the EMA
during their review process in an effort to bring pixantrone to
patients for whom there are currently no available drugs in this
setting,” said James A. Bianco, M.D., CEO of CTI.

The EMA’s review of the MAA will follow the centralized
marketing authorization procedure and, if the MAA is approved,
Pixuvri expects to receive marketing authorization in the E.U.
member states.

The Company also plans, in 2011, to submit a marketing
application in selected other countries beginning with
Switzerland.

Pixantrone was initially granted orphan drug status by the EMA
for the treatment of diffuse large B-cell lymphoma (DLBCL), but
based on the expansion of the current MAA to the broader aggressive
NHL population, CTI has agreed to withdraw the orphan designation
from the E.U. register.

About PixantronePixantrone is a novel aza-anthracenedione
that has distinct structural and physio-chemical properties that
make its anti-tumor activity unique in this class of agents.
Similar to anthracyclines, pixantrone inhibits Topo-isomerase II
but unlike anthracyclines–rather than intercalation with
DNA–pixantrone alkylates DNA–forming stable DNA adducts, with
particular specificity for CpG rich, hyper-methylated sites. We
believe that these structural differences resulted in significantly
enhanced anti-lymphoma activity compared to doxorubicin in
preclinical models. In addition

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech